All In Biotech

Drug Trial Radar · NCT07030257

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

Aug 15, 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Tasca TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests

Conditions

  • Solid Tumor Malignancies
  • Colorectal Carcinoma
  • Small Cell Lung Cancer ( SCLC )
  • Head and Neck (HNSCC)
  • Bladder Cancer
  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer, Advanced or Metastatic

Interventions

  • CP-383Drug

    Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Determine the maximum tolerated dose (MTD)Time frame: 21 days
  2. Part 2: Evaluate the efficacy of CP-383 at the recommended phase 2 dose in selected tumor typesTime frame: From enrollment through study completion, an average of 1 year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists-Lake Nona

    Orlando, Florida · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • NEXT Oncology - Dallas

    Dallas, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.